Payment overview · 2025
General Payments
$9,377.83
21 reported records · 5 companies
Healthcare provider profile · identity verified
Adam David Devore
Allopathic & Osteopathic Physicians|Internal Medicine · DURHAM, NC · NPI 1558560987
Verified facts
What the public records show
CMS Open Payments records show Adam David Devore received $9,377.83 in general payments during 2025 across 21 reported records.
ABIOMED accounted for 53.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $5,031.55 | 53.6% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $1,570.00 | 16.7% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $1,514.36 | 16.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $1,245.00 | 13.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.92 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $6,265.00 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500.00 | 1 |
| Travel and Lodging | $947.32 | 4 |
| Food and Beverage | $665.51 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,514.36 | 2 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 1127 | 228 |
| Prednisone | Prednisone | 1038 | 245 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 972 | 252 |
| Tacrolimus | Tacrolimus | 950 | 184 |
| Pravastatin Sodium | Pravastatin Sodium | 691 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 156 |
| Carvedilol | Carvedilol | 509 | 127 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 396 | 87 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 322 | 68 |
| Ezetimibe | Ezetimibe | 282 | 81 |
| Entresto | Sacubitril/Valsartan | 279 | 62 |
| Eliquis | Apixaban | 278 | 69 |
| Spironolactone | Spironolactone | 260 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 71 |
| Jardiance | Empagliflozin | 237 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 225 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 52 |
| Furosemide | Furosemide | 202 | 71 |
| Gabapentin | Gabapentin | 201 | 50 |
| Sertraline Hcl | Sertraline Hcl | 197 | 37 |
| Losartan Potassium | Losartan Potassium | 192 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 188 | 52 |
| Torsemide | Torsemide | 187 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 31 |
| Sirolimus | Sirolimus | 158 | 31 |
| Trazodone Hcl | Trazodone Hcl | 153 | 36 |
| Potassium Chloride | Potassium Chloride | 143 | 43 |
| Allopurinol | Allopurinol | 140 | 34 |
| Cyclosporine Modified | Cyclosporine, Modified | 132 | 24 |
| Valganciclovir Hcl | Valganciclovir Hcl | 128 | 43 |
| Lisinopril | Lisinopril | 122 | 40 |
| Propranolol Hcl | Propranolol Hcl | 117 | 29 |
| Omeprazole | Omeprazole | 99 | 24 |
| Metformin Hcl | Metformin Hcl | 98 | 24 |
| Azathioprine | Azathioprine | 88 | 14 |
| Eplerenone | Eplerenone | 80 | 23 |
| Levetiracetam | Levetiracetam | 78 | 13 |
| Mirtazapine | Mirtazapine | 74 | 14 |
| Mycophenolic Acid | Mycophenolate Sodium | 70 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 14 |
| Finasteride | Finasteride | 67 | 11 |
| Nystatin | Nystatin | 66 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 13 |
| Farxiga | Dapagliflozin Propanediol | 64 | 18 |
| Valacyclovir | Valacyclovir Hcl | 64 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 23 |
| Gengraf | Cyclosporine, Modified | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 12 |
| Pregabalin | Pregabalin | 46 | 13 |
| Prograf | Tacrolimus | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 32 |
| Atovaquone | Atovaquone | 44 | 13 |
| Famotidine | Famotidine | 44 | 12 |
| Labetalol Hcl | Labetalol Hcl | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 13 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | suppressed |
| Envarsus Xr | Tacrolimus | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Entecavir | Entecavir | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Neoral | Cyclosporine, Modified | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Corlanor | Ivabradine Hcl | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Cresemba | Isavuconazonium Sulfate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,377.83 · 21 records | ABIOMED | ACCOLADE SR, LifeVest | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error